Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
Only InfantInternational journal of molecular sciences · 2024
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 3 countries.
Jacqueline FischerDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Estelle ErknerDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Rahel FitzelDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Pia RadszuweitDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Hildegard KeppelerDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Fulya KorkmazDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Giovanni RotiDepartment of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
Claudia LengerkeDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.ORCID 0000-0001-5442-2805
Dominik SchneidawindDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
Corina SchneidawindDepartment of Medicine II, University Hospital Tuebingen, Eberhard Karls University, 72076 Tuebingen, Germany.
University of Tübingen · DEUniversity Hospital of Zurich · CHUniversity of Parma · IT
Funding
Clinician Scientist Program of the Faculty of Medicine Tuebingen 390-0-0Deutsche Forschungsgemeinschaft 442788847Deutsche José Carreras Leukämie-Stiftung 04R/2019IZKF Promotionskolleg of University Tuebingen 2021-2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Uncovering NOTCH1 as a Promising Target in the Treatment of · full record | OpenQuestion